Aduhelm: Development or Dissension?

By Minitha Jacob, PharmD Candidate, and Hannah Grice, PharmD Alzheimer’s disease (AD) is considered the most common cause of dementia and accounts for about 60% of cases (approximately 5.7 million adults) in the US. Alzheimer’s is primarily seen in patients aged 65 years and older. Statistics predict the number of cases to double by 2050.1 […]

Aduhelm: The New Alzheimer’s Drug and its Coverage Implications with Alzheimer’s Disease

by Giftina Wilson, PharmD Candidate On June 7, 2021, the FDA approved the controversial Aduhelm® (aducanumab) for treating Alzheimer’s Disease despite inadequate evidence of the drug’s efficacy based on a highly debated posthoc analysis.1 Currently, there is an ongoing discussion on whether Medicare will provide coverage of this new antibody to its beneficiaries. Aduhelm is […]